John P. A. Ioannidis
Stanford University
Publications 1226
#1Clément Palpacuer (French Institute of Health and Medical Research)H-Index: 4
Last.Florian NaudetH-Index: 12
view all 6 authors...
Different methodological choices such as inclusion/exclusion criteria and analytical models can yield different results and inferences when meta-analyses are performed. We explored the range of such differences, using several methodological choices for indirect comparison meta-analyses to compare nalmefene and naltrexone in the reduction of alcohol consumption as a case study. All double-blind randomized controlled trials (RCTs) comparing nalmefene to naltrexone or one of these compounds to a pl...
#1Yuan Jin Tan (Stanford University)H-Index: 1
#2Ryan J. Crowley (Stanford University)
Last.John P. A. IoannidisH-Index: 147
view all 0 authors...
Comparative clinical trials of domestic dogs with spontaneously-occurring cancers are increasingly common. Canine cancers are likely more representative of human cancers than induced murine tumors. These trials could bridge murine models and human trials and better prioritize drug candidates. Such investigations also benefit veterinary patients. We aimed to evaluate the design and reporting practices of clinical trials containing ≥2 arms and involving tumor-bearing dogs. 163 trials containing 85...
#1Miquel Tortella-Feliu (UIB: University of the Balearic Islands)H-Index: 13
#2Miquel A. FullanaH-Index: 17
Last.Lorena Fernández de la Cruz (KI: Karolinska Institutet)H-Index: 12
view all 19 authors...
Abstract Approximately one third of individuals who experience a severe traumatic event will develop posttraumatic stress disorder (PTSD). It is crucial to identify what factors may be associated with increased or decreased risk for PTSD. We conducted an umbrella review of systematic reviews and meta-analyses of risk/protective factors for PTSD and assessed and graded the evidence of the association between each factor and PTSD. Thirty-three systematic reviews and meta-analyses were included and...
#1Don van RavenzwaaijH-Index: 12
#2Rei Monden (UG: University of Groningen)H-Index: 4
Last.John P. A. Ioannidis (HHMI: Howard Hughes Medical Institute)
view all 4 authors...
BACKGROUND: In clinical trials, study designs may focus on assessment of superiority, equivalence, or non-inferiority, of a new medicine or treatment as compared to a control. Typically, evidence in each of these paradigms is quantified with a variant of the null hypothesis significance test. A null hypothesis is assumed (null effect, inferior by a specific amount, inferior by a specific amount and superior by a specific amount, for superiority, non-inferiority, and equivalence respectively), af...
#1Patrick Liu (Yale University)H-Index: 4
#2John P. A. IoannidisH-Index: 147
Last.Joshua D. Wallach (Yale University)H-Index: 7
view all 0 authors...
There is growing interest in evaluating differences in healthcare interventions across routinely collected demographic characteristics. However, individual subgroup analyses in randomized controlled trials are often not prespecified, adjusted for multiple testing, or conducted using the appropriate statistical test for interaction, and therefore frequently lack credibility. Meta-analyses can be used to examine the validity of potential subgroup differences by collating evidence across trials. He...
#2Anna M. Blom (Lund University)H-Index: 53
Last.John D. Lambris (UPenn: University of Pennsylvania)H-Index: 93
view all 0 authors...
Therapeutic innovations of potentially great clinical impact should embrace the overarching values of research accountability, data transparency and validation through the scientific peer-review process.
#1Tian Yang (Edin.: University of Edinburgh)
#2Xue Li (Edin.: University of Edinburgh)H-Index: 5
Last.Evropi Theodoratou (Edin.: University of Edinburgh)H-Index: 4
view all 10 authors...
#1Soo-Yon Rhee (Stanford University)H-Index: 28
#2Philip M. Grant (Stanford University)H-Index: 13
Last.Robert W. Shafer (Stanford University)H-Index: 69
view all 7 authors...